Facebook
Twitter
LinkedIn
Forward
A Case-Based Interactive Discussion of the ASTRO Clinical Practice Guideline for HPV-Positive Oropharyngeal Squamous Cell Carcinoma
This case-based activity is designed to provide learners with practical guidance on management of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) and highlight areas of uncertainty where there may be a range of acceptable treatment approaches. HPV-associated OPSCC continues to increase worldwide. Due to the improved prognosis of HPV-associated OPSCC and growing population of survivors, prospective studies have focused on reducing the long-term effects of treatment by "de-intensifying" standard therapies, including surgery, radiation therapy (RT) and systemic therapy. The goal of such studies is to maintain cure rates and minimize the acute and long-term effects of treatment. Additionally, there is variation in post-treatment imaging assessment and use of ctDNA-based biomarkers. In the face of prospective and retrospective studies with varying treatment approaches, there can be clinician uncertainty about clinical management of patients with HPV-associated OPSCC treated with definitive or postoperative RT, particularly regarding RT dosing, fractionation, incorporation of systemic therapy, and use of imaging and biomarker-based response assessment. ASTRO convened a multi-disciplinary taskforce with representatives from ASCO and AHNS to review the existing literature and provide guidance for clinical management of patients with HPV-associated OPSCC.
Topics:
- Case 1/Guidelines Presentation and Discussion
Danielle N. Margalit, MD, MPH - Moderator
Full Panel - Case 2/Guidelines Presentation and Discussion
Danielle N. Margalit, MD, MPH - Moderator
Full Panel - Case 3/Guidelines Presentation and Discussion/Q and A
Danielle N. Margalit, MD, MPH - Moderator
Full Panel
This activity is available from April 15, 2025, through 11:59 p.m. Eastern time on April 14, 2027.
The content was originally presented and recorded at the 2024 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, radiation therapists, radiation dosimetrists, radiation biologists residents and specialists in oral medicine, dentistry and otolaryngology.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Integrate systemic therapy in treatment of HPV-associated OPSCC.
- Identify indications for postoperative RT and postoperative chemoradiotherapy.
- Use a range of acceptable doses/fractionation schemes for definitive and postoperative RT and discuss achievable target metrics for organs-at-risk sparing in treatment planning for bilateral and ipsilateral neck treatment.
- Danielle N. Margalit, MD, MPH, is employed by Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Harvard Medical School. Dr. Margalit serves as Chair of the Head and Neck Appropriate Use Criteria Committee of the American Radium Society.
- David Jonathan Sher, MD, FASTRO, MPH, is employed by University of Texas Southwestern Medical Center.
- Paul L. Swiecicki, MD, is employed by University of Michigan. Dr. Swiecicki receives grant/research funding and salary support from Ascentage Pharma. Dr. Swiecicki is co-developer and patent holder for a novel ctDNA assay.
- Musaddiq Javvad Awan, MD, is employed by Medical College of Wisconsin. Dr. Awan receives grant/research funding from Genentech and NIH. Dr. Awan is a committee member with NRG Oncology.
- Christina H. Chapman, MD, MS, is employed by Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine.
- Joseph Califano, MD, is employed by UC San Diego.
The person(s) above served as the developer(s) of this activity. Additionally, the ASTRO Education Committee had control over the content of this activity. All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
- Student/Graduate Student/PGY-1 Member: $49
- Postdoctoral Fellow Member: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until April 14, 2027, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.